Accepted Manuscript



Title: Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells

Author: Aimee C. Talleur, Brandon M. Triplett, Sara Federico, Ewelina Mamcarz, William Janssen, Jianrong Wu, David Shook, Wing Leung, Wayne L. Furman

PII: S1083-8791(17)30581-5
DOI: http://dx.doi.org/doi: 10.1016/j.bbmt.2017.07.011
Reference: YBBMT 54734

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 10-5-2017
Accepted date: 12-7-2017

Please cite this article as: Aimee C. Talleur, Brandon M. Triplett, Sara Federico, Ewelina Mamcarz, William Janssen, Jianrong Wu, David Shook, Wing Leung, Wayne L. Furman, Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells, *Biology of Blood and Marrow Transplantation* (2017), http://dx.doi.org/doi: 10.1016/j.bbmt.2017.07.011.

Consolidation therapy for newly diagnosed pediatric high-risk neuroblastoma patients using busulfan/melphalan, autologous hematopoietic cell transplant, anti-GD2 antibody, GM-CSF, IL-2 and haploidentical NK cells

Aimee C. Talleur[1], Brandon M. Triplett[1], Sara Federico[2], Ewelina Mamcarz[1], William Janssen[1], Jianrong Wu[3], David Shook[1], Wing Leung[1] and Wayne L. Furman[2]

[1]Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee

[2]Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee

[3]Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee

Key Words: GD2 monoclonal antibody; neuroblastoma; autologous transplant; immunotherapy; NK cells

Running title: Combination therapy for pediatric high-risk neuroblastoma

Corresponding author:
Wayne L. Furman
262 Danny Thomas Place, Mailstop 260, Memphis TN 38105
Phone 901-595-3300
Fax 901-595-2220
Wayne.furman@stjude.org

Funding sources: This work was supported by the St. Jude Children's Research Hospital Comprehensive Cancer Center Support Grant (2 P30 CA021765), American Lebanese Syrian Associated Charities, Cookies for Kids' Cancer and Cure Childhood Cancer Foundation

Financial Disclosure statement: The authors have no financial disclosures.

Conflict of Interest statement: The authors have no conflicts of interest to disclose.